Total Payments
$42,400
2024 Payments
$1,688
Companies
33
Transactions
535
Medicare Patients
10,562
Medicare Billing
$2.6M
Payment Breakdown by Category
Other$19,562 (46.1%)
Food & Beverage$14,498 (34.2%)
Travel$4,662 (11.0%)
Consulting$2,875 (6.8%)
Education$801.88 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,563 | 12 | 46.1% |
| Food and Beverage | $14,498 | 398 | 34.2% |
| Travel and Lodging | $4,662 | 9 | 11.0% |
| Consulting Fee | $2,875 | 5 | 6.8% |
| Education | $801.88 | 111 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16,635 | 117 | $0 (2023) |
| Boston Scientific Corporation | $6,313 | 52 | $0 (2024) |
| Lilly USA, LLC | $3,438 | 6 | $0 (2020) |
| BIOTRONIK INC. | $2,766 | 16 | $0 (2022) |
| Cardiovascular Systems Inc. | $1,930 | 8 | $0 (2017) |
| Medtronic Vascular, Inc. | $1,572 | 10 | $0 (2020) |
| Amarin Pharma Inc. | $1,257 | 61 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $1,046 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,040 | 37 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,002 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,688 | 57 | E.R. Squibb & Sons, L.L.C. ($268.08) |
| 2023 | $2,535 | 86 | Merck Sharp & Dohme LLC ($368.79) |
| 2022 | $6,854 | 73 | Boston Scientific Corporation ($4,702) |
| 2021 | $1,643 | 39 | BOSTON SCIENTIFIC CORPORATION ($862.17) |
| 2020 | $4,326 | 50 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,113) |
| 2019 | $13,140 | 124 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,894) |
| 2018 | $8,622 | 60 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,322) |
| 2017 | $3,592 | 46 | Cardiovascular Systems Inc. ($1,930) |
All Payment Transactions
535 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: Cardiology | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $31.06 | General |
| Category: Cardio-renal | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.42 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $118.82 | General |
| 09/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.85 | General |
| Category: Cardiovascular | ||||||
| 08/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $7.93 | General |
| Category: Cardiovascular | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $32.62 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $28.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: Cardiology | ||||||
| 08/02/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 07/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/17/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Not Applicable | ||||||
| 07/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Diabetes | ||||||
| 07/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: Cardio-renal | ||||||
| 06/28/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.33 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,537 | 7,047 | $1.6M | $733,469 |
| 2022 | 21 | 2,813 | 12,524 | $1.5M | $731,973 |
| 2021 | 21 | 2,674 | 11,802 | $1.2M | $548,584 |
| 2020 | 23 | 2,538 | 11,314 | $1.2M | $552,624 |
Total Patients
10,562
Total Services
42,687
Medicare Billing
$2.6M
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 71 | 71 | $213,000 | $143,184 | 67.2% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 90 | 90 | $225,000 | $142,798 | 63.5% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 161 | 322 | $321,600 | $132,658 | 41.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 699 | 1,182 | $290,772 | $131,978 | 45.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 247 | 249 | $135,456 | $50,773 | 37.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 136 | 136 | $50,864 | $19,448 | 38.2% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 18 | 20 | $20,000 | $15,838 | 79.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 100 | 400 | $60,400 | $15,739 | 26.1% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 192 | 194 | $43,068 | $13,706 | 31.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 26 | 26 | $37,496 | $12,380 | 33.0% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 71 | 71 | $21,300 | $10,091 | 47.4% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 26 | 52 | $19,400 | $8,859 | 45.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 41 | $13,530 | $6,539 | 48.3% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 21 | 21 | $14,049 | $5,232 | 37.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 37 | 65 | $9,230 | $4,827 | 52.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 306 | 356 | $17,800 | $4,798 | 27.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $9,100 | $4,104 | 45.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 37 | $5,846 | $2,664 | 45.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $5,544 | $2,239 | 40.4% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 23 | 25 | $5,500 | $1,676 | 30.5% |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | Office | 2023 | 86 | 3,510 | $25,210 | $1,404 | 5.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 21 | $3,528 | $1,222 | 34.6% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2023 | 70 | 70 | $1,050 | $520.29 | 49.6% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 18 | 20 | $3,000 | $465.80 | 15.5% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 30 | 30 | $7,500 | $325.20 | 4.3% |
About Dr. John Lien, MD
Dr. John Lien, MD is a Cardiovascular Disease healthcare provider based in San Jose, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932291648.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Lien, MD has received a total of $42,400 in payments from pharmaceutical and medical device companies, with $1,688 received in 2024. These payments were reported across 535 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,563).
As a Medicare-enrolled provider, Lien has provided services to 10,562 Medicare beneficiaries, totaling 42,687 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location San Jose, CA
- Active Since 09/29/2006
- Last Updated 04/10/2009
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1932291648
Products in Payments
- JARDIANCE (Drug) $19,530
- WATCHMAN Access System (Device) $4,690
- Coronary Orbital Atherectomy System (Device) $1,859
- Reveal LINQ (Device) $1,311
- Vascepa (Drug) $1,257
- WATCHMAN (Device) $1,094
- XARELTO (Drug) $1,046
- VERQUVO (Drug) $916.03
- ENTRESTO (Drug) $885.26
- ELIQUIS (Drug) $624.85
- FARXIGA (Drug) $473.85
- WATCHMAN FLX (Device) $392.30
- CAMZYOS (Drug) $385.02
- Repatha (Biological) $372.97
- PRADAXA (Drug) $268.16
- TRADJENTA (Drug) $264.04
- Ozempic (Drug) $257.56
- Adempas (Drug) $229.01
- EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) (Device) $213.31
- Arcalyst (Drug) $201.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Jose
Dr. Mohammed Qayyum, Md, MD
Cardiovascular Disease — Payments: $195,680
Cardiovascular Disease $195,680
Andrew Kwa, M.d, M.D
Cardiovascular Disease — Payments: $137,381
Cardiovascular Disease $137,381
Matthew Levy, M.d, M.D
Cardiovascular Disease — Payments: $66,907
Cardiovascular Disease $66,907
Dr. Thirupathi Reddy, Md, MD
Cardiovascular Disease — Payments: $41,933
Cardiovascular Disease $41,933
John Kao, M.d, M.D
Cardiovascular Disease — Payments: $21,794
Cardiovascular Disease $21,794
Mehrdad Rezaee, Md Phd, MD PHD
Cardiovascular Disease — Payments: $20,025
Cardiovascular Disease $20,025